Selpercatinib (Retsevmo®) for NSCLC. HTA ID: 21021

Assessment Status Awaiting HTA submission from Applicant
HTA ID 21021
Drug Selparcatinib
Brand Retsevmo®
Indication For the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Assessment Process
Rapid review commissioned 08/06/2021
Rapid review completed 29/06/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/07/2021
Pre-submission consultation with Applicant 11/01/2022

The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.